Literature DB >> 15206721

The mechanism of interferon-gamma induced anti Toxoplasma gondii by indoleamine 2,3-dioxygenase and/or inducible nitric oxide synthase vary among tissues.

Suwako Fujigaki1, Masao Takemura, Hidetsugu Hamakawa, Mitsuru Seishima, Kuniaki Saito.   

Abstract

L-Tryptophan degradation by indoleamine 2,3-dioxygenase (IDO) induction and reactive nitrogen intermediates produced by inducible nitric oxide synthase (iNOS) induction are important factors for IFN-gamma-induced anti-toxoplasma activities. In the present study, the effects of acute Toxoplasma gondii (T. gondii) infection on IDO and iNOS were investigated using wild-type (WT) and IFN-gamma gene-deficient (IFN-gamma KO) mice. In the WT C57BL/6J mice, enzyme activities and mRNA levels of IDO in both lung and brain were markedly increased, and lung L-tryptophan concentrations were dramatically decreased following infection. In contrast, these metabolic changes did not occur in infected IFN-gamma KO mice. The level of iNOS induction in the infected IFN-gamma KO mice was high in lung and low in brain compared to that in infected WT mice. The extent of increased mRNA expression of T. gondii surface antigen gene 2 (SAG2) in lung and brain induced by infection was significantly enhanced in the IFN-gamma KO mice compared to that in WT mice. Treatment with N-nitro-L-arginine methyl ester, an iNOS inhibitor, increased the levels of SAG2 mRNA in brain, but not in lung following infection. This in vivo study provides evidence that L-tryptophan depletion caused by T. gondii is directly mediated by IFN-gamma in the lung, where iNOS is not induced by IFN-gamma. This study suggests that there is an anti-toxoplasma mechanism of cross-regulation between iNOS and IDO and that the expression of main anti-parasite effector mechanisms of iNOS and/or IDO may vary among tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15206721     DOI: 10.1007/978-1-4615-0135-0_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells.

Authors:  Christine Roshick; Heidi Wood; Harlan D Caldwell; Grant McClarty
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production.

Authors:  Michael J Brumlik; Srilakshmi Pandeswara; Sara M Ludwig; Duane P Jeansonne; Michelle R Lacey; Kruthi Murthy; Benjamin J Daniel; Rong-Fu Wang; Suzanne R Thibodeaux; Kristina M Church; Vincent Hurez; Mark J Kious; Bin Zhang; Adebusola Alagbala; Xiaojun Xia; Tyler J Curiel
Journal:  Exp Parasitol       Date:  2013-03-27       Impact factor: 2.011

3.  A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence.

Authors:  Dunja Hinze-Selch; Walter Däubener; Lena Eggert; Sükran Erdag; Renate Stoltenberg; Sibylle Wilms
Journal:  Schizophr Bull       Date:  2007-03-26       Impact factor: 9.306

4.  Deficiency in indoleamine-2, 3-dioxygenase induces upregulation of guanylate binding protein 1 and inducible nitric oxide synthase expression in the brain during cerebral infection with Toxoplasma gondii in genetically resistant BALB/c mice but not in genetically susceptible C57BL/6 mice.

Authors:  Namrata Anand; Jenny Lutshumba; Megan Whitlow; Mohamed H Abdelaziz; Rajesh Mani; Yasuhiro Suzuki
Journal:  Microbes Infect       Date:  2021-11-13       Impact factor: 9.570

5.  Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis.

Authors:  Weiping Hou; Suzhi Li; Yinping Wu; Xiang Du; Fahuan Yuan
Journal:  Clin Exp Immunol       Date:  2009-03-11       Impact factor: 4.330

Review 6.  Toxoplasmosis: Targeting neurotransmitter systems in psychiatric disorders.

Authors:  Tooran Nayeri; Shahabeddin Sarvi; Ahmad Daryani
Journal:  Metab Brain Dis       Date:  2021-09-03       Impact factor: 3.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.